Premium
Outcomes of contrast‐induced nephropathy: Experience in patients undergoing cardiovascular intervention
Author(s) -
McCullough Peter
Publication year - 2006
Publication title -
catheterization and cardiovascular interventions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.988
H-Index - 116
eISSN - 1522-726X
pISSN - 1522-1946
DOI - 10.1002/ccd.20658
Subject(s) - medicine , contrast induced nephropathy , percutaneous coronary intervention , conventional pci , dialysis , nephropathy , myocardial infarction , coronary artery disease , stroke (engine) , cardiology , intensive care medicine , surgery , diabetes mellitus , mechanical engineering , engineering , endocrinology
Use of iodinated contrast media for diagnostic and interventional procedures is increasing as computed tomography and percutaneous coronary intervention (PCI) technologies provide increasing patient benefit. Although some complications associated with contrast media are mild and transient, contrast‐induced nephropathy (CIN) can negatively affect long‐term patient morbidity and mortality. The incidence of and outcomes from CIN have been carefully studied in cardiology patients. A number of studies have identified CIN‐associated complications in PCI patients, including bleeding, hematoma, stroke, adult respiratory distress syndrome, electrolyte imbalances, and sepsis. In post‐PCI patients, rates of myocardial infarction and vessel reocclusion are more common in patients with CIN. Therefore, in‐hospital mortality is increased in patients with CIN. In patients requiring dialysis after PCI, several studies have shown the 1‐year mortality rate to be >55%. Even moderate renal dysfunction not requiring dialysis is associated with increased mortality in patients with coronary artery disease. Precautionary measures before, during, and after the use of contrast media that reduce the incidence of CIN, such as discontinuation of nephrotoxic medications, adequate hydration, and use of appropriate volumes and types of contrast media, should be considered in all patients with renal insufficiency or with other risk factors for CIN. © 2006 Wiley‐Liss, Inc.